A new paper argues that the addition of a single data element—namely, a batch or lot number—would enhance the value of pharmacovigilance systems for biosimilars.
Pharmacovigilance is important for any new drug, but it is especially key in tracking the safety of biologics in the era of biosimilar market entry. A paper recently published in the Journal of Managed Care & Specialty Pharmacy argues that the addition of a single data element—namely, a batch or lot number—would enhance the value of pharmacovigilance systems.
In the paper, Sreedhar Sagi, PhD; Hillel P. Cohen, PhD; and Gillian R. Woollett, MA, DPhil, explain that they sought to identify the most effective data element by which to immediately attribute an adverse event to a specific medicine, and found that, while current pharmacovigilance systems are adequate, adding more data could prove useful.
The authors examined records from the Sandoz post-marketing safety databases representative of approximately 350 million patient days of treatment with Sandoz-sponsored biosimilars to somatropin, epoetin alfa, and filgrastim. Because multiple product names were used for the same products in different markets, the results, collected in a single database, allowed for insight into pharmacovigilance capabilities for dealing with multiple names for a given therapy. They also investigated periodic safety update reports and supplemented their data with information available on biologics from the Danish Medicines Agency.
While some have suggested that brand names are not sufficient for biologic and biosimilar pharmacovigilance, the authors report that spontaneous adverse drug reaction reports are made with the use of the brand name in the majority of cases, and that there is no evidence that the nonproprietary name is a common identifier (nor is there evidence that it is a source of confusion). In the case of epoetin alfa, 355 reports were identified. Only 8 reports did not identify a specific brand. Somatropin generated 1603 reports, among which the brands of 35 were unknown. Finally, filgrastim was responsible for 533 reports, among which 36 did not specify a brand.
However, inclusion of batch and lot records would allow any issue related to specific batches or lots of a product to be captured swiftly. The authors suggest that these data points could be recorded by either healthcare providers or pharmacists, and that a barcode system, such as the one implemented in the European Union, would facilitate real-time recording. The United States, the authors note, is developing a legislatively mandated initiative to use a standardized numerical identifier to record product information.
Whatever the methodology, inclusion of batch/lot information should allow for the grouping of medicines by shared attributes (such as active pharmaceutical ingredient), brand name or manufacturer and nonproprietary name, and specific batches and lots of an individual medicine. These 3 attributes, the authors say, “allow maximal pooling of data in a manner that can lead to more timely decisions.”
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.